 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
Multiple Myeloma
Multiple myeloma is cancer that begins in plasma cells, a type of white blood cell. Plasma cells are white blood cells that make antibodies. Antibodies are part of the immune system. They work with other parts of the immune system to help protect the body from germs and other harmful substances. [Source: www.cancer.gov]
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. How to use this system:The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.
1. Select a clinical trial that you feel best suits your (or the participant's)
health condition. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Multiple Myeloma Study CLBH589B2206
The purpose of this clinical trial is to find out the effects, both positive and negative, of a study drug called LBH589 when administered together with oral lenalidomide and dexamethasone to people who have a form of bone marrow cancer called Multiple Myeloma that has not responded to prior treatments. The study drug LBH589 is being tested as part of this study and is currently not available for purchase on the market in any country.
Trial phase: Phase 1 Participation Duration: Participants will be required to take 3 drugs over a 28 day period. They will take oral LBH589 once-a-day on Monday, Wednesday, and Friday each week. In addition, they will take lenalidomide once-a-day, and dexamethasone once-a-day on specific days during the 28 day treatment cycle. Participants will be asked to come to the clinic one to four times each week. Each of these visits should take about 1-3 hours, but there are a few visits that may take up to 8 hours. Protocol Number: CLBH589B2206 Multiple Myeloma Study CLBH589B2207
The purpose of this clinical trial is to find out the effects, both positive and negative, of a study drug called LBH589 when administered together with bortezomib to people who have a form of bone marrow cancer called Multiple Myeloma that has not responded to prior treatments. The study drug LBH589 is being tested as part of this study and is currently not available for purchase on the market in any country.
Trial phase: Phase 1 Participation Duration: Participants will take oral LBH589 once-a-day on Monday, Wednesday, and Friday each week. In addition, participants will receive an injection of bortezomib twice weekly for 2 weeks. Participants will be asked to come to the clinic for five visits in the first week of the study, with the frequency of visits reducing thereafter for the length of participation in the study. Each of these visits should take about 1-3 hours, but there are a few visits that may take up to 8 hours. Protocol Number: CLBH589B2207 |
